Colorectal cancer: how emerging molecular understanding affects treatment decisions.

Meera Sridharan, Joleen M. Hubbard, Axel Grothey

Research output: Contribution to journalArticle

Abstract

The medical treatment of metastatic colorectal cancer (mCRC) has advanced significantly over the last 10 years as the result of the introduction of several active cytotoxic and biologic agents into standard clinical practice. Several recent phase III trials reported median overall survival data exceeding 30 months, an achievement inconceivable only 5 years ago.The first major step forward in the medical management of mCRC was provided by the addition of irinotecan and oxaliplatin to fluorouracil-based therapy; this increased survival from about 12 months to about 20 months.The introduction of biologic agents such as vascular endothelial growth factor inhibitors and epidermal growth factor inhibitors further increased survival--to more than 2 years in prospective trials. Recently, an expanding array of molecular prognostic and predictive biomarkers have been developed that are being integrated into clinical practice. In this review we discuss the current treatment options in metastatic colon cancer, with a special focus on biologic agents and how molecular understanding guides treatment decisions.

Original languageEnglish (US)
Pages (from-to)110-118
Number of pages9
JournalOncology (Williston Park, N.Y.)
Volume28
Issue number2
StatePublished - 2014
Externally publishedYes

Fingerprint

Biological Factors
Colorectal Neoplasms
irinotecan
oxaliplatin
Cytotoxins
Epidermal Growth Factor
Fluorouracil
Colonic Neoplasms
Vascular Endothelial Growth Factor A
Biomarkers
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Colorectal cancer : how emerging molecular understanding affects treatment decisions. / Sridharan, Meera; Hubbard, Joleen M.; Grothey, Axel.

In: Oncology (Williston Park, N.Y.), Vol. 28, No. 2, 2014, p. 110-118.

Research output: Contribution to journalArticle

@article{6d1c1fab67ff4410a2b98255a695fd5f,
title = "Colorectal cancer: how emerging molecular understanding affects treatment decisions.",
abstract = "The medical treatment of metastatic colorectal cancer (mCRC) has advanced significantly over the last 10 years as the result of the introduction of several active cytotoxic and biologic agents into standard clinical practice. Several recent phase III trials reported median overall survival data exceeding 30 months, an achievement inconceivable only 5 years ago.The first major step forward in the medical management of mCRC was provided by the addition of irinotecan and oxaliplatin to fluorouracil-based therapy; this increased survival from about 12 months to about 20 months.The introduction of biologic agents such as vascular endothelial growth factor inhibitors and epidermal growth factor inhibitors further increased survival--to more than 2 years in prospective trials. Recently, an expanding array of molecular prognostic and predictive biomarkers have been developed that are being integrated into clinical practice. In this review we discuss the current treatment options in metastatic colon cancer, with a special focus on biologic agents and how molecular understanding guides treatment decisions.",
author = "Meera Sridharan and Hubbard, {Joleen M.} and Axel Grothey",
year = "2014",
language = "English (US)",
volume = "28",
pages = "110--118",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - Colorectal cancer

T2 - how emerging molecular understanding affects treatment decisions.

AU - Sridharan, Meera

AU - Hubbard, Joleen M.

AU - Grothey, Axel

PY - 2014

Y1 - 2014

N2 - The medical treatment of metastatic colorectal cancer (mCRC) has advanced significantly over the last 10 years as the result of the introduction of several active cytotoxic and biologic agents into standard clinical practice. Several recent phase III trials reported median overall survival data exceeding 30 months, an achievement inconceivable only 5 years ago.The first major step forward in the medical management of mCRC was provided by the addition of irinotecan and oxaliplatin to fluorouracil-based therapy; this increased survival from about 12 months to about 20 months.The introduction of biologic agents such as vascular endothelial growth factor inhibitors and epidermal growth factor inhibitors further increased survival--to more than 2 years in prospective trials. Recently, an expanding array of molecular prognostic and predictive biomarkers have been developed that are being integrated into clinical practice. In this review we discuss the current treatment options in metastatic colon cancer, with a special focus on biologic agents and how molecular understanding guides treatment decisions.

AB - The medical treatment of metastatic colorectal cancer (mCRC) has advanced significantly over the last 10 years as the result of the introduction of several active cytotoxic and biologic agents into standard clinical practice. Several recent phase III trials reported median overall survival data exceeding 30 months, an achievement inconceivable only 5 years ago.The first major step forward in the medical management of mCRC was provided by the addition of irinotecan and oxaliplatin to fluorouracil-based therapy; this increased survival from about 12 months to about 20 months.The introduction of biologic agents such as vascular endothelial growth factor inhibitors and epidermal growth factor inhibitors further increased survival--to more than 2 years in prospective trials. Recently, an expanding array of molecular prognostic and predictive biomarkers have been developed that are being integrated into clinical practice. In this review we discuss the current treatment options in metastatic colon cancer, with a special focus on biologic agents and how molecular understanding guides treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=84901001387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901001387&partnerID=8YFLogxK

M3 - Article

C2 - 24701697

VL - 28

SP - 110

EP - 118

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -